BamSEC and AlphaSense Join Forces
Learn More

CERo Therapeutics Holdings Inc. – Material Contracts

OTC: CERO    
Share price (5/22/26): $0.02    
Market cap (5/22/26): $925 thousand
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 1 page Fourth Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Common Stock Purchase Agreement Dated as of November 26, 2025 by and Among CERo Therapeutics Holdings, Inc. and Keystone Capital Partners, LLC
12/34/56
EX-10.6
from 10-Q 6 pages This Amendment and Limited Waiver Agreement (This “Agreement”) Is Entered Into as of August 13, 2025, by CERo Therapeutics Holdings, Inc. (The “Company”) and the Investor Signatory Hereto (The “Holder”)
12/34/56
EX-10.5
from 10-Q 11 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Amendment No. 1 to Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 30 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 49 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Common Stock Purchase Agreement Dated as of July 11, 2025 by and Among CERo Therapeutics Holdings, Inc. and Keystone Capital Partners, LLC
12/34/56
EX-10.2
from 8-K 11 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Amendment No. 1 to Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 4 pages Offer Letter
12/34/56
EX-10.1
from 8-K 5 pages Offer Letter
12/34/56
EX-10.1
from 8-K 1 page Third Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 5 pages Consent Agreement
12/34/56
EX-10.2
from 8-K 29 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 55 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 30 pages Securities Purchase Agreement
12/34/56
EX-10.25
from S-1/A 14 pages Placement Agency Agreement
12/34/56
EX-10.24
from S-1/A 35 pages Securities Purchase Agreement
12/34/56
EX-10.25
from S-1/A 14 pages Placement Agency Agreement
12/34/56